Communiqués Aligos Therapeutics, Inc.

Actions

ALGS

US01626L2043

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 15/07/2026			Varia. 5j.	Varia. 1 janv.
5,770 ^USD	-5,49%		-14,26%	-38,09%

13/07	Aligos Therapeutics achève le recrutement pour l'étude de phase 2 B-SUPREME sur le pevifoscorvir sodique dans le traitement de l'hépatite B chronique	CI
13/07	Aligos Therapeutics achève le recrutement pour l'étude de phase 2 d'un traitement potentiel contre l'hépatite B chronique	MT

Communiqués

13/07	Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection	AQ
06/07	Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection	AQ
27/05	Aligos Therapeutics Presents Positive Data at the EASL Congress 2026	AQ
13/05	Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026	AQ
08/05	Aligos Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results	AQ
30/04	Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026	AQ
27/04	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
24/04	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
16/04	Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection	AQ
14/04	Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation	AQ
05/03	Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results	AQ
26/02	Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026	AQ
23/02	Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI)	AQ
02/02	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
30/01	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
21/01	Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates	AQ
13/01	Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer	AQ
12/12	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
11/12	Aligos Therapeutics Presents Positive Data at HEP-DART 2025	AQ
17/11	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
14/11	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
10/11	Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2025	AQ
06/11	Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results	AQ
04/11	Aligos Therapeutics to Present at Upcoming Investor Conferences	AQ